Prognostic value of serum CYFRA21‐1 and CEA for non‐small‐cell lung cancer
Authors:
Open Access
- 2 September 2015
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 4 (11) , 1633-1638
Abstract
The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment (CYFRA21‐1) and carcinoembryonic antigen (CEA) for non‐small‐cell lung cancer (NSCLC) patients. Literatures related to effects of serum CYFRA21‐1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI. Meta‐analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio (HR) in all NSCLC patients with high‐level serum CYFRA21‐1 was 1.64 (95% CI 1.46–1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28–1.65, P < 0.001). Serum CYFRA21‐1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.Keywords
This publication has 21 references indexed in Scilit:
- Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancerRadiation Oncology Journal, 2014
- The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancerTumor Biology, 2012
- Therapeutic advances in non-small cell lung cancerThorax, 2011
- Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinibExperimental and Therapeutic Medicine, 2011
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2007
- Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinibLung Cancer, 2007
- Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New BiomarkersJournal of Thoracic Oncology, 2007
- Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I diseaseThe Annals of Thoracic Surgery, 2004
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung CancerNew England Journal of Medicine, 2004